The complexity and paradigm shift in the management of PsA
The place of the JAK inhibitor (tofacitinib citrate) in the RA treatment paradigm
Immune Mediated Inflammatory Disease (IMID) – Day 2
IL-23 inhibition – An Emerging Treatment for Psoriatic Arthritis
Real world evidence of Baricitinib in the management of Rheumatoid Arthritis
Emerging Insights in the Treatment of Psoriasis Arthritis (PsA)
Role of IL-23 in the Management of Psoriatic Arthritis (PsA)
